Nucleotide Excision Repair and Anti-cancer Chemotherapy

Overview

Journal Cytotechnology

Specialties Biotechnology
Genetics

Date 2008 Nov 13

PMID 19002792

Citations 10

Authors

E Reed

Affiliations

Soon will be listed here.

Abstract

DNA repair is an important effector of anti-cancer drug resistance. In recent years, it has become apparent that DNA repair is an extremely complex process. Processes within DNA repair that may contribute to one or more drug resistance phenotypes include; O-6-alkyltransferase activity, base excision repair, mismatch repair, nucleotide excision repair, and gene specific repair. Clearly, several of these processes may show increased activity within any single cell, or tumor, at any one time. This review attempts to touch briefly upon the question of the distinctions between each of these specific pathways; and then seeks to expand on nucleotide excision repair as a possible effector of cellular and clinical resistance to platinum-based anticancer therapy.

Citing Articles

Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.

Lin C, Liu T, Lai J, Yang S, Tsao T Int J Med Sci. 2017; 14(13):1410-1417.

PMID: 29200955 PMC: 5707758. DOI: 10.7150/ijms.21938.

Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.

Wang W, Zhang L, Liu L, Zheng Y, Zhang Y, Yang S Oncol Rep. 2017; 37(4):1989-1997.

PMID: 28260069 PMC: 5367362. DOI: 10.3892/or.2017.5443.

A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.

Zhang Y, Ma J, Zhang S, Deng G, Wu X, He J Int J Colorectal Dis. 2015; 30(9):1173-83.

PMID: 26054387 DOI: 10.1007/s00384-015-2273-z.

Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.

Li S, Zhu L, Yao L, Xia L, Pan L BMC Gastroenterol. 2014; 14:154.

PMID: 25175730 PMC: 4156636. DOI: 10.1186/1471-230X-14-154.

β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.

Li Q, Lee R, Liang H, Wang G, Li J, Zhong Y Int J Oncol. 2013; 43(3):721-8.

PMID: 23817665 PMC: 3787889. DOI: 10.3892/ijo.2013.1996.

References

Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, DArrigo A . GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science. 1995; 268(5219):1912-4. DOI: 10.1126/science.7604265. View

Rowinsky E, Gilbert M, McGuire W, Noe D, Grochow L, Forastiere A . Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991; 9(9):1692-703. DOI: 10.1200/JCO.1991.9.9.1692. View

Reed E, Yuspa S, Zwelling L, Ozols R, Poirier M . Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest. 1986; 77(2):545-50. PMC: 423377. DOI: 10.1172/JCI112335. View

Sancar A . Mechanisms of DNA excision repair. Science. 1994; 266(5193):1954-6. DOI: 10.1126/science.7801120. View

Kastan M, Canman C, Leonard C . P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995; 14(1):3-15. DOI: 10.1007/BF00690207. View

Bitton R, Figg W, Reed E . A preliminary risk-benefit assessment of paclitaxel. Drug Saf. 1995; 12(3):196-208. DOI: 10.2165/00002018-199512030-00005. View

Parker R, Dimery I, Dabholkar M, Vionnet J, Reed E . Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy. Int J Oncol. 2011; 3(2):331-5. DOI: 10.3892/ijo.3.2.331. View

van Duin M, de Wit J, Odijk H, Westerveld A, Yasui A, Koken M . Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell. 1986; 44(6):913-23. DOI: 10.1016/0092-8674(86)90014-0. View

Karran P . Appropriate partners make good matches. Science. 1995; 268(5219):1857-8. DOI: 10.1126/science.7604258. View

10.

Drummond J, Li G, Longley M, Modrich P . Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science. 1995; 268(5219):1909-12. DOI: 10.1126/science.7604264. View

11.

Shivji K, Kenny M, Wood R . Proliferating cell nuclear antigen is required for DNA excision repair. Cell. 1992; 69(2):367-74. DOI: 10.1016/0092-8674(92)90416-a. View

12.

Rowinsky E, Citardi M, Noe D, Donehower R . Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol. 1993; 119(12):727-33. DOI: 10.1007/BF01195344. View

13.

Parker R, Gill I, Tarone R, Vionnet J, Grunberg S, Muggia F . Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis. 1991; 12(7):1253-8. DOI: 10.1093/carcin/12.7.1253. View

14.

Drapkin R, Sancar A, Reinberg D . Where transcription meets repair. Cell. 1994; 77(1):9-12. DOI: 10.1016/0092-8674(94)90228-3. View

15.

Yu J, Reed E, Mu C, Bostickbruton F . Demonstration of a polymorphism in the gene ERCC1 by two DNA sequencing methods. Oncol Rep. 2011; 4(5):905-7. DOI: 10.3892/or.4.5.905. View

16.

Parker R, Dabholkar M, Lee K, Reed E . Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr. 1993; (15):83-8. View

17.

Dabholkar M, Berger M, Vionnet J, Egwuagu C, Silber J, Yu J . Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res. 1995; 55(6):1261-6. View

18.

Wahl A, Donaldson K, Fairchild C, Lee F, Foster S, Demers G . Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996; 2(1):72-9. DOI: 10.1038/nm0196-72. View

19.

States J, Reed E . Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Lett. 1996; 108(2):233-7. DOI: 10.1016/s0304-3835(96)04428-x. View

20.

Lee K, Parker R, Bohr V, Cornelison T, Reed E . Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis. 1993; 14(10):2177-80. DOI: 10.1093/carcin/14.10.2177. View